2. Search Result
Search Result
Pathways Recommended: Epigenetics
Results for "

Epigenetic Agent.

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16438
    RRx-001
    Maximum Cited Publications
    20 Publications Verification

    Nibrozetone

    		 CD47 Apoptosis Parasite Infection Inflammation/Immunology Cancer
    RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity . RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α . RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity .
    RRx-001
  • HY-103019
    Enitociclib
    2 Publications Verification

    (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib

    		 Drug Isomer CDK Apoptosis DNA/RNA Synthesis Inflammation/Immunology Cancer
    Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor (IC50=3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II. Enitociclib specifically depletes key short-lived proteins such as c-MYC, MCL-1 and induces tumor cell apoptosis. Enitociclib also interferes with the production of enhancer RNAs (eRNA) and enhancer-promoter interactions, and downregulates oncogene expression at the epigenetic level. Enitociclib exerts synergistic effects with agents including Bortezomib (HY-10227), Lenalidomide (HY-A0003), Pomalidomide (HY-10984), Venetoclax (HY-15531) and Paclitaxel (HY-B0015), and even reverses paclitaxel resistance. Enitociclib serves as a vital research tool for various malignancies such as double-hit diffuse large B-cell lymphoma, multiple myeloma and pancreatic ductal adenocarcinoma .
    Enitociclib
  • HY-W030778
    Nitrilotriacetic acid
    1 Publications Verification

    Triglycollamic acid

    		 Biochemical Assay Reagents Others
    Nitrilotriacetic acid is an orally active chelating agent for metal ions. Nitrilotriacetic acid is an aminotricarboxylic acid that can sequester metal ions as water soluble complexes. Nitrilotriacetic acid reacts with strong oxidizing agents such as hypochlorite, chlorine, ozone, or oxygen in the presence of palladium/carbon catalyst. Nitrilotriacetic acid interacts with solid phases such as cell membranes and bone matrices in the mammalian system. Nitrilotriacetic acid is classified as an epigenetic rodent carcinogen .
    Nitrilotriacetic acid
  • HY-160084
    2′-Deoxy-4′-thiocytidine

    		DNA Methyltransferase Cancer
    2′-Deoxy-4′-thiocytidine (T-dCyd) is a novel epigenetic agent. 2′-Deoxy-4′-thiocytidine administrations led to a significant p21 increase. 2′-Deoxy-4′-thiocytidine can eradicate of tumor cells in the double-mutant xenografts .
    2′-Deoxy-4′-thiocytidine
  • HY-W030778R
    Nitrilotriacetic acid (Standard)

    Triglycollamic acid (Standard)

    		 Biochemical Assay Reagents Reference Standards Others
    Nitrilotriacetic acid (Standard) is the analytical standard of Nitrilotriacetic acid. This product is intended for research and analytical applications. Nitrilotriacetic acid is an orally active chelating agent for metal ions. Nitrilotriacetic acid is an aminotricarboxylic acid that can sequester metal ions as water soluble complexes. Nitrilotriacetic acid reacts with strong oxidizing agents such as hypochlorite, chlorine, ozone, or oxygen in the presence of palladium/carbon catalyst. Nitrilotriacetic acid interacts with solid phases such as cell membranes and bone matrices in the mammalian system. Nitrilotriacetic acid is classified as an epigenetic rodent carcinogen .
    Nitrilotriacetic acid (Standard)
  • HY-W974306
    DML3

    		DNA/RNA Synthesis Cancer
    DML3, a 5-methylcytosine DNA glycosylase, is a DNA demethylating agent. DML3 specifically recognizes and excises 5-methylcytosine (5-meC) from DNA through a base excision repair mechanism. DML3 is promising for research of plant epigenetic regulation and cancers .
    DML3
  • HY-103019R
    Enitociclib (Standard)

    (+)-BAY-1251152 (Standard); (+)-VIP152 (Standard); (S)-Enitociclib (Standard)

    		 Reference Standards Drug Isomer Apoptosis DNA/RNA Synthesis CDK Cancer
    Enitociclib (Standard) is the analytical standard of Enitociclib (HY-103019). This product is intended for research and analytical applications. Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor (IC50=3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II. Enitociclib specifically depletes key short-lived proteins such as c-MYC, MCL-1 and induces tumor cell apoptosis. Enitociclib also interferes with the production of enhancer RNAs (eRNA) and enhancer-promoter interactions, and downregulates oncogene expression at the epigenetic level. Enitociclib exerts synergistic effects with agents including Bortezomib (HY-10227), Lenalidomide (HY-A0003), Pomalidomide (HY-10984), Venetoclax (HY-15531) and Paclitaxel (HY-B0015), and even reverses paclitaxel resistance. Enitociclib serves as a vital research tool for various malignancies such as double-hit diffuse large B-cell lymphoma, multiple myeloma and pancreatic ductal adenocarcinoma .
    Enitociclib (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: